取代-1,3-二氢吲哚-2-酮化合物的合成

取代苯胺经酰化、环合反应制得关键中间体取代靛红衍生物4a～4k,再用三乙基硅烷/三氟乙酸体系室温还原制得取代-1,3-二氢吲哚-2-酮类化合物1a～1k,后者可用于合成舒尼替尼等酪氨酸激酶抑制剂类抗肿瘤药.     

3-取代吲哚酮类化合物的合成及抗肿瘤活性

目的设计合成具有抗肿瘤活性的3-取代吲哚-2-酮类化合物,并对其抗肿瘤活性进行评价.方法以吲哚酮和苯甲醛衍生物在微波辐射条件下进行缩合反应制得目标化合物,用人肝癌HepG2细胞进行抗肿瘤活性检测.结果合成了8个化合物,其中6个未见报道.其结构均经1H-NMR、IR及ESI-MS确证.结论初步抗肿瘤活性测试结果显示化合物Ⅱe、Ⅱg有较强的活性(IC50值分别为1.4μmol·L-1和1.2μmol·L-1,小于阳性对照药5-Fu).微波辐射技术用于3-取代吲哚酮的合成,能大幅度缩短反应时间,提高收率.     

3-取代2-吲哚酮类化合物的合成与抗肿瘤活性研究

目的寻找新的具有血管内皮细胞生长因子受体酪氨酸激酶抑制活性的3-取代2-吲哚酮类化合物。方法以2-吲哚酮为原料，利用缩合反应合成目标化合物，并进行体外初步药效学评价。结果设计并合成了5种化合物，其中4种为首次发现，体外初步药效学研究表明，所合成的化合物均具有抑制S-180肿瘤细胞生长的活性，其中化合物Ⅱ活性最强。结论3-取代2-吲哚酮类化合物具有抑制S-180肿瘤细胞生长的活性，化合物中吲哚环平面与相应的芳环平面之间处于垂直状态时活性较强。     

5-羟基-6-溴-1H-吲哚-3-羧酸酯类衍生物的合成及其体外抗病毒活性

目的 设计合成5-羟基-6-溴-1H-吲哚-3-羧酸乙酯类化合物,评价其抗流感病毒和抗呼吸道合胞病毒活性.方法 经1H-NMR和MS确证目标化合物结构,并经体外抗病毒试验测定其抗病毒活性.结果与结论 合成了11个未见文献报道的5-羟基-6-溴-1H-吲哚-3-羧酸乙酯类化合物.初步活性试验表明,11个目标化合物均具有一定的抑制流感病毒和呼吸道合胞病毒作用,其中,化合物X9的体外抗病毒作用与阳性对照药物金刚烷胺相当.     

N-芳酰基取代的二氢吲哚-3-乙酸类衍生物的设计、合成与体外降糖活性研究

目的:设计、合成N-芳酰基取代的二氢吲哚-3-乙酸类衍生物,并评价其体外降糖活性。方法:以吲哚衍生物2-[5-(苄氧基)-1-(4-氯苯甲酰基)-2-甲基-1H-吲哚-3-基]乙酸(GY3)为先导化合物,以4-苯甲氧基苯肼盐酸盐及4-氧戊酸甲酯为原料,经Fischer吲哚环合、还原、酰胺化及水解等4步反应得到8种N-芳酰基(3-羟基苯甲酰基、3-氰基苯甲酰基、4-硝基苯甲酰基、4-甲磺酰基苯甲酰基、4-乙酰胺基苯甲酰基、3-乙酰氨基苯甲酰基、异烟酰基、吡啶-2-甲酰基)取代的二氢吲哚-3-乙酸类衍生物。采用人肝癌细胞HepG2测试目标化合物的体外促葡萄糖消耗活性。结果:共合成8个N-芳酰基取代的二氢吲哚-3-乙酸类目标化合物,其结构均经质谱、核磁共振氢谱及碳谱确证。在1.0μmol/L条件下,所合成化合物在HepG2细胞上的促葡萄糖消耗百分率为5.4%～9.1%,其中,2-[(2R,3S)-5-苄氧基-2-甲基-1-(4-甲磺酰基苯甲酰基)-2,3-二氢-吲哚-3-基]乙酸的降糖活性最好,其促葡萄糖消耗百分率为(9.10±1.81)%,与阳性对照药物二甲双胍接近[(10.58±1.68)%],但仍弱于先导化合物GY3[(12.15±0.78)%]。结论:二氢吲哚类化合物的N-芳酰基芳环上引入不同吸电子取代基团,如氰基、硝基、甲磺酰基等,其降糖活性不同程度下降,且弱于卤素取代基的GY3。     

5-羟基-1H-吲哚-3-羧酸乙酯类化合物的合成及其抗流感病毒活性

目的设计合成5-羟基-1H-吲哚-3-羧酸乙酯类化合物,评价其抗流感病毒和抗呼吸道合胞病毒活性.方法经IR、1H-NMR和MS确证目标物结构,并经体外抗病毒试验进行活性筛选.结果与结论合成了9个5-羟基-1H-吲哚-3-羧酸乙酯类化合物,初步活性试验表明,具有一定的抑制流感病毒和呼吸道合胞病毒作用,其中,化合物Ⅷ1、Ⅷ2、Ⅷ5的抗病毒活性与利巴韦林和阿比朵尔相当.     

1H-1,2,3-三氮唑乙酸酯衍生物的合成与体外抗乙肝病毒活性研究

目的 设计合成1H-1,2,3-三氮唑环衍生物，并测定其体外抗乙肝病毒活性。方法 以取代吲哚为原料，经取代、环加成反应得到14个目标化合物，通过¹H-NMR、¹³C-NMR和MS方法对化合物的结构进行表征，以HepG2.2.15为细胞模型进行抗乙肝病毒体外活性实验，测试化合物在体外对乙肝病毒e抗原(HBeAg)和乙肝病毒表面抗原(HBsAg)分泌的影响。结果与结论其中4个目标化合物能较好地抑制HBeAg和HBsAg的分泌，化合物2-(4-((5-氯-1H-吲哚-1-基)甲基)-1H-1,2,3-三唑-1-基)乙酸乙酯(IC₅₀=75.41μmol·L^-1,SI=9.23)能较好抑制HBV DNA。吲哚5号位含有吸电子基团卤素原子的化合物对抑制乙肝病毒的分泌效果较好。     

5-三氟甲基-3-(4-甲基-1H-咪唑-1-基)苯胺的合成

3,5-二硝基三氟甲苯(2)与氟化四甲铵进行氟代反应,所得单氟中间体再与4-甲基-1H-咪唑进行取代反应得到5-三氟甲基-3-(4-甲基-1H-咪唑-1-基)-硝基苯(3),然后在Pd/C催化下氢化还原制得抗肿瘤药尼罗替尼的中间体5-三氟甲基-3-(4-甲基-1H-眯唑-1-基)-苯胺(1),总收率约50％(以2计).     

1-(5-取代糠基)吲哚啉-2-酮衍生物的合成和初步抗肿瘤活性

为了寻找具有较好抗肿瘤活性的新型吲哚啉-2-酮类化合物，本研究以5-甲酰基-2,4-二甲基-1H-吡咯-3-羧酸乙酯与5位不同取代的吲哚啉-2-酮(2a～2d)为原料，首先经缩合得3-吡咯亚甲基-吲哚啉-2-酮(3a～3d)，再经N烃化反应得到1-(5-甲酰基糠基)-3-(吡咯亚甲基)-吲哚啉-2-酮(4a～4d)，然后与吲哚啉-2-酮缩合得到以5-亚甲基糠基连接的双吲哚啉-2-酮化合物(5a～5d)。所合成的12个新型吲哚啉-2-酮类化合物的结构经核磁共振谱、质谱和元素分析确认。采用四氮唑盐(MTT)还原法测试所合成化合物的体外抗肿瘤活性，结果表明所合成的化合物均有一定的抗肿瘤作用，其中6个化合物对SPC-A1肺癌肿瘤株体外抑制活性优于舒尼替尼，特别是化合物5a～5d， IC₅₀值均小于5 μmol·L^-1，值得作为抗肿瘤药物先导化合物。     

1,1,2-三甲基-1H-苯并[e]吲哚的制备

目的合成1,1,2-三甲基-1H-苯并[e]吲哚。方法由2-萘胺经重氮化反应、还原反应制得2-萘肼,再与甲基异丙基酮经费歇尔吲哚合成反应制得目标化合物。结果与结论经熔点测定及1H-NMR分析确证目标化合物结构,总收率为26.4%。     

A new sesquiterpene lactone from Tsoongiodendron odorum Chun.

A new sesquiterpene lactone (1) was obtained from the cytotoxic fraction of 95% ethanol extract of root barks of Tsoongiodendron odorum Chun together with two known sesquiterpene lactones, costunolide (2) and parthenolide (3). The structure of 1 was elucidated as 5alpha, 6alpha, 7beta, 10beta- 11alpha, 13-dihydro-4(15)-eudesmene-12, 6-olide on the basis of chemical and spectral evidence including X-ray diffraction analysis. Costunolide showed cytotoxic activity against human leukemia (HL-60) cell line. Parthenolide showed promising cytotoxic activities in vitro against HCT-8, Bel-7402, SKOV3, KB, HELA and EJ cell lines. Also, the cytotoxic ethyl acetate fraction of ethanol extract of the root barks from which three chemical components were isolated showed promising cytotoxic activities in vitro against KB, BGC-823, Bel-7402, HCT-8, HL-60 cell lines.     

The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig

The present study investigated the role of the 5-hydroxytryptamine (5-HT, serotonin)1D receptor as a presynaptic autoreceptor in the guinea pig. In keeping with the literature, the 5-HT1B selective antagonist, 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro [furo[2,3-f]indole-3,4'-piperidine]oxalate (SB224289) potentiated [3H]5-HT outflow from pre-labelled slices of guinea pig cerebral cortex confirming its role as a presynaptic autoreceptor in this species. In addition, the 5-HT1D receptor-preferring antagonists, 1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]-ethyl]-3-pyridin-4-yl-methyl-tetrahydro-pyrimidin-2-one (LY367642), (R)-1-[2-(4-(6-fluoro-1H-indol-3-yl-)-3,6-dihydro-1(2H)-pyridinyl)ethyl]-3,4-dihydro-1H-2-benzopyran-6-carboxamide (LY456219), (S)-1-[2-(4-(6-fluoro-1H-indol-3-yl-)-3,6-dihydro-1(2H)-pyridinyl)ethyl]-3,4-dihydro-1H-2-benzopyran-6-carboxamide (LY456220) and 1-[2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl]-3,3-dimethyl-1,2-dihydro-indol-2-one (LY310762), potentiated [3H]5-HT outflow from this preparation with potencies (EC50 values=31-140 nM) in the same range as their affinities for the guinea pig 5-HT1D receptor (Ki values=100-333 nM). The selective 5-HT1D receptor agonist, R-2-(4-fluoro-phenyl)-2-[1-[3-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-propyl]-piperidin-4-ylamino]-ethanol dioxylate (L-772,405), inhibited [3H]5-HT outflow. In microdialysis studies, administration of either SB224289 or LY310762 at 10 mg/kg by the intraperitoneal (i.p.) route, potentiated the increase in extracellular 5-HT concentration produced by a maximally effective dose of the selective serotonin re-uptake inhibitor, fluoxetine (at 20 mg/kg i.p.). In addition, the 5-HT1D receptor-preferring antagonist and 5-HT transporter inhibitor, LY367642 (at 10 mg/kg i.p.), elevated extracellular 5-HT concentrations to a greater extent than a maximally effective dose of fluoxetine. It is concluded that the 5-HT1D receptor, like the 5-HT1B receptor, may be a presynaptic autoreceptor in the guinea pig.     

Synthesis and anti-HIV activity of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) amino]-N(4,6-dimethyl-2-pyrimidinyl)-benzene sulfonamide and its derivatives

4-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene) amino]-N(4,6-dimethyl-2-pyrimidinyl)-benzene sulphonamide and its derivatives were synthesized by reaction of isatin and its derivatives with sulphadimidine. Their chemical structures have been confirmed by IR, ¹H NMR data and elemental analysis. Investigation of anti-HIV activity of compounds were tested against replication of HIV-1 (IIIB) and HIV-2 (ROD) strains in acutely infected MT-4 cells and the activity compared with standard azidothymidine. Among the compounds tested, 4-[(1,2-dihydro-2 oxo-3H-indol-3-ylidene)amino]-N(4,6-dimethyl-2-pyrimidinyl)-benzene sulphonamide and its N-acetyl derivative were the most active compounds.     

Synthesis and In Vitro Antioxidant Activity of New 3-Substituted-2-Oxindole Derivatives

A series of new 1,3-dihydro-3-hydroxy-3-(2-phenyl-2-oxoethyl)-2H-indol-2-ones (1a-g) and 1,3-dihydro-3-(2-phenyl-2-oxoethylidene)-2H-indol-2-ones (2a-g) were synthesised by Knoevenagel condensation of substituted indole-2,3-diones (isatins) with various acetophenones. The synthesised compounds were characterised by their physical data, elemental, IR, ¹H NMR, ¹³C NMR and mass spectral analyses and their in vitro antioxidant activity was determined by 2,2-diphenyl-1-picrylhydrazyl free radical scavenging assay. These compounds showed moderate to good antioxidant activities as compared with the standard, ascorbic acid. The antioxidant potential of 3-hydroxy-3-substituted oxindoles (1a-g) increased in a concentration-dependent manner from 10 to 500 μg/ml with 5-fluoro and 5-methyl analogues showing maximum activity. Of 3-aroyl methylene indol-2-ones (2a-g), majority of compounds with halogen substitution at position 5 of isatin ring exhibited good antioxidant activity within a concentration range of 5-100 μg/ml and the maximum activity was observed at 20 and 25 μg/ml concentrations. Thus, our study provides evidence that some newly synthesised isatin derivatives exhibit substantial antioxidant activity at low concentrations.     

Synthesis and antibacterial activity of 2-substituted 6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.

A series of 2-substituted 6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids was prepared and evaluated for antibacterial activity. The 6-fluoro-2-methyl-1-prenyl-1,4-dihydro-7-(3,5-dimethylpiperazinyl)-4-oxo-3-quinolinecarboxylic acid (14f) exhibited the most potent antibacterial activity against gram-positive bacteria among the total 32 derivatives. The synthetic strategies involve the use of well known keto ester condensation of benzoyl chloride and reductive cyclization of intermediates (4a-d) to afford 4-hydroxy-1,2-dihydro-2-oxo-quinoline derivatives (5a,b) or 1-hydroxy-1,4-dihydro-4-oxo-quinoline derivatives (6a,b).     

A New Sesquiterpene Lactone from Tsoongiodendron Odorum Chun

Abstract

A new sesquiterpene lactone (1) was obtained from the cytotoxic fraction of 95% ethanol extract of root barks of Tsoongiodendron odorum Chun together with two known sesquiterpene lactones, costunolide (2) and parthenolide (3). The structure of 1 was elucidated as 5α, 6α, 7β, 10β-11α, 13-dihydro-4(15)-eudesmene-12, 6-olide on the basis of chemical and spectral evidence including X-ray diffraction analysis. Costunolide showed cytotoxic activity against human leukemia (HL-60) cell line. Parthenolide showed promising cytotoxic activities in vitro against HCT-8, Bel-7402, SKOV3, KB, HELA and EJ cell lines. Also, the cytotoxic ethyl acetate fraction of ethanol extract of the root barks from which three chemical components were isolated showed promising cytotoxic activities in vitro against KB, BGC-823, Bel-7402, HCT-8, HL-60 cell lines.     

A Structured–Activity Relationship Study of Batracylin Analogues

A number of isoindolo[l ,2-b]quinazolines and some benzo[4,5]isoquinolino[l,2-b]quinazolines as structural modification analogues of the antitumor compound batracylin were synthesized and evaluated against HL-60 cell growth and in topoisomerase II-mediated DNA cleavage assays. Of the compounds studied, 10,12-dihydro-7,8-methy lenedioxyisoindolo[ 1,2-b] quinazolin-12(10H)-one (1d), 2-amino-10,12-dihydroisoindolo[l ,2-b]quinazolin- 12(10H)-one (1p), and 2-amino-7,8-methylenedioxy-10,12-dihydroisoindolo[l ,2-b]quinazolin-12(10H)-one (1ab) exhibited good inhibitory activities against HL-60 cell lines as well as induction of topo II-mediated DNA cleavage activities.     

Synthesis and anti-HIV activity of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) amino]-N(4,6-dimethyl-2-pyrimidinyl)-benzene sulfonamide and its derivatives.

4-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene) amino]-N(4,6-dimethyl-2-pyrimidinyl)-benzene sulphonamide and its derivatives were synthesized by reaction of isatin and its derivatives with sulphadimidine. Their chemical structures have been confirmed by IR, (1)H NMR data and elemental analysis. Investigation of anti-HIV activity of compounds were tested against replication of HIV-1 (IIIB) and HIV-2 (ROD) strains in acutely infected MT-4 cells and the activity compared with standard azidothymidine. Among the compounds tested, 4-[(1,2-dihydro-2 oxo-3H-indol-3-ylidene)amino]-N(4,6-dimethyl-2-pyrimidinyl)-benzene sulphonamide and its N-acetyl derivative were the most active compounds.     

Synthesis and antileukemic activity of new 3-(5-methylisoxazol-3-yl) and 3-(pyrimidin-2-yl)-2-styrylquinazolin-4(3H)-ones

3-(3-Methylisoxazol-5-yl) and 3-(pyrimidin-2-yl)-2-styrylquinazolin-4(3H)-ones 8a-l and 9a,c-e,h-l were synthesized by refluxing in acetic acid the corresponding 2-methylquinazolinones 6 and 8 with the opportune benzoic aldehyde for 12 h. The synthesized styrylquinazolinones 8a-l and 9a,c-e,h-l were tested in vitro for their antileukemic activity against L-1210 (murine leukemia), K-562 (human chronic myelogenous leukemia) and HL-60 (human leukemia) cell lines showing in some cases good activity.     

Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives

We report herein the synthesis and biological evaluation of two series of 7-substituted norfloxacin derivatives. Most compounds tested in this study demonstrated better activity against methicillin-resistant Staphylococcus aureus than norfloxacin. Preliminary in vitro evaluation indicated that the 7-[4-(2-hydroxyiminoethyl)piperazin-1-yl] derivatives 3b-e possess distinct cytotoxicity profiles as compared with their alpha-methylene-gamma-butyrolactone counterparts, 4b,e: i.e., excellent activities against the renal cancer subpanel. Among them, 1-ethyl-6-fluoro-7-?4-[2-(4-chlorophenyl)-2-hydroxyiminoethyl]-1-p ipe razinyl?-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (3d) demonstrated the most significant activities against renal cancer cell lines, with log GI(50) values of -6.40 against CAK-1, -6.14 against RXF 393, and -7.54 against UO-31, compared with a mean log GI(50) value of -5.03.